While TÜBİTAK demonstrates its approach of “developing together and achieving together” against the difficulties within the scope of combating the new type of coronavirus (Kovid-19), it also carries out activities to strengthen its ecosystem in cancer research.
According to the information compiled by the AA correspondent, ecosystem actors with cancer research benefit from important programs of TUBITAK such as Industry Doctorate and National and International Leading Researchers.
With scientific and technological developments, studies are also being carried out on cancer treatments that may be much different in the coming years. New solutions for cancer are being developed with advances in cancer immunotherapy, disease-treating genome editing, precision medicine and digitalization in healthcare.
Diagnostic and therapeutic developments
Here, while identifying new therapeutic agents in lung cancer, 19 different peptides have been identified on the cell surface specific to lung cancer to develop a diagnostic system.
In another project, a genetically modified warrior T-cell-based therapy system is being developed. T cells, which are immune system cells, are genetically modified to make them susceptible to cancerous cells and conditioning them to destroy them.
Development is also being made in the project of developing targeted molecules suitable for the use of photodynamic therapy for both diagnosis and treatment of tumors. In this context, while 2 unique photodynamic therapy agents are being produced, a biosimilar drug project for cancer treatment is also carried out.
TÜBİTAK, the relevant institution of the Ministry of Industry and Technology, also puts forward the “developing together and achieving together” approach against the difficulties in the fight against Kovid-19.